Retatrutide vs Semaglutide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Retatrutide is a first-in-class GLP-1/GIP/glucagon triple receptor agonist by Eli Lilly. Phase 2 trials demonstrated up to 24.2% weight loss at 48 weeks - surpassing all previously approved agents. Phase 3 trials actively enrolling for obesity and type 2 diabetes....
Calculate Retatrutide dose →Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It mimics endogenous GLP-1 to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite centrally. Once-weekly subcutaneous dosing; clini...
Calculate Semaglutide dose →| Parameter | Retatrutide | Semaglutide |
|---|---|---|
| Category | Metabolic / Triple Incretin Agonist | Metabolic / GLP-1 Agonist |
| Research | Phase 3 Clinical Trials | FDA Approved |
| Half-Life | ~6 days | ~168 hours (7 days) |
| Typical Dose | 1-24 mg/week (Phase 2); Phase 3 doses TBD | 0.25-2.4 mg/week (SC); 3-14 mg/day (oral) |
| Frequency | Once weekly | Once weekly (SC); once daily (oral) |
| Route | Subcutaneous injection | Subcutaneous injection; oral tablet |
| FDA Status | Phase 3 (obesity, T2D); not yet approved | Approved (T2D, obesity) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.